MAP2K7 and non-small cell lung carcinoma: Our findings indicated that treatment with the MEK inhibitor trametinib plus the RTK inhibitor anlotinib significantly inhibited the growth of KRAS-mutant NSCLC cells (G12C, G12D, G12V, G12S, and Q61H).